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ABSTRACT  
Hundreds of new psychoactive substances (NPS) have emerged in the drug market over the last 
decade. Few drug surveys in the United States, however, ask about use of NPS, so prevalence and 
correlates of use are largely unknown. A large portion of NPS use is unintentional or unknown as 
NPS are common adulterants in drugs like ecstasy/Molly, and most NPS are rapidly eliminated 
from the body, limiting efficacy of urine, blood, and saliva testing. We utilized a novel method of 
examining prevalence of NPS use in a high-risk population utilizing hair-testing. Hair samples from 
high-risk nightclub and dance music attendees were tested for 82 drugs and metabolites (including 
NPS) using ultra-high performance liquid chromatography-tandem mass spectrometry. Eighty 
samples collected from different parts of the body were analyzed, 57 of which detected positive for 
at least one substance—either a traditional or new drug. Among these, 26 samples tested positive 
for at least one NPS—the most common being butylone (25 samples). Other new drugs detected 
include methylone, methoxetamine, 5/6-APB, α-PVP, and 4-FA. Hair analysis proved a powerful 
tool to gain objective biological drug-prevalence information, free from possible biases of 
unintentional or unknown intake and untruthful reporting of use. Such testing can be used actively 
or retrospectively to validate survey responses and inform research on consumption patterns, 
including intentional and unknown use, polydrug-use, occasional NPS intake, and frequent or heavy 
use.   
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INTRODUCTION  
Hundreds of new psychoactive substances (NPS) have emerged in the drug market in the 
last decade, taking advantage of the delay occurring between their introduction into the market and 
their legal ban. NPS tend to mimic the psychotropic effects of traditional drugs of abuse, but their 
acute and chronic toxicity, and side-effects are largely unknown. This has led to funneling of 
resources worldwide to outline the phenomenon, identify the molecules, describe effects, interpret 
or update existing laws, enact new regulations, and develop appropriate and effective analytical 
methods for their identification in biological fluids and seized materials (1-9).  
Unfortunately, little is known about the current diffusion of NPS among the general 
population or in high-risk populations. Few surveys query NPS use and there is increasing evidence 
that much NPS use is actually unknown or unintentional as they are common adulterants in drugs 
like ecstasy/MDMA/Molly (10-13). Most NPS are also eliminated from the urine, blood, and saliva 
of users within hours or days, which limits the ability of toxicological confirmation. This is a 
serious concern, especially in cases of hospitalizations and deaths resulting from intentional or 
unintentional use. A further challenge to detection of NPS in the biological matrices commonly 
tested, especially urine, is posed by the extensive, yet insufficiently investigated, metabolic 
transformation that these substances possibly undergo once introduced in the human body. In 
practice, most routine analyses do not presently include screening procedures for NPS, preventing 
clear knowledge of the consumption of these new drugs in the population. As a consequence, a 
number of unresolved issues are raised, including the number and variety of NPS present in 
different countries, frequency of their use, and the social features of users.  
To circumvent the limitations of urine, blood, and saliva testing, the detection of NPS in hair 
samples was recently proposed as a practical means to provide preliminary information on the black 
market penetration of NPS in specific territories and populations (14-18). The keratin matrix 
incorporates the parent NPS consumed over extended time periods, providing access to a much 
wider diagnostic window than urine. This feature, combined with the analytical performances of the 
last generation ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-
MS/MS) instruments (8), allows researchers to obtain significant information about past use, even a 
single intake, of any targeted NPS, with older periods of use corresponding to the hair segments 
more distant from the hair root (19,20). 
In the present study, we considered the specific population of electronic dance music (EDM) 
nightclubs and festivals attendees in New York City (NYC), as a high-risk population particularly 
exposed to both intentional and unintentional NPS intake (21,22). Information on NPS prevalence 
in the US via biological confirmation tends to be limited to drug confiscations (23,24), but we 
tested hair analysis as a potential  tool to gain objective biological drug-prevalence information in 
the context of an epidemiology study, free from possible biases of unintentional or unknown intake 
and untruthful reporting of use. Inclusion of both traditional drugs and NPS in the screening allows 
us to distinguish different consumption patterns, including co-use, occasional NPS intake, and 
frequent or heavy use. To our knowledge, this is the first large epidemiology study to examine 
biological hair results of NPS use in this high-risk scene in the US. We believe these biological 
results with retrospective capability complement both surveys and analysis of biological fluids 
conducted in EDM festivals population and can help encourage future testing and inform 
prevention.   
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EXPERIMENTAL 
Study protocol 
679 nightclub and festival attendees in NYC were surveyed from July through September of 
2015. Participants were surveyed outside of ten different venues (including two dance festivals) 
over 21 days. Participants were eligible if they identified as age 18-25 and were about to attend the 
randomly selected party (21). After providing informed consent and taking a survey, participants 
were asked if they were willing to donate a hair sample to be tested for “new drugs” such as ”bath 
salts”. If the participant agreed, the trained recruiter collected the sample by cutting a small lock of 
hair (~100 hairs) from as close to the participant’s scalp as possible. Hair was cut with a clean 
scissor (wiped with an alcohol-wipe after each use), folded up in a piece of tin foil, and stored in a 
small envelope labeled with the participant’s anonymous study ID number. In some cases, male 
participants volunteered t  have the recruiter to clip or buzz (with an electronic buzzer) body hair 
from the arm, chest, or leg. Of the 679 participants surveyed, 80 (11.8%) provided a hair sample 
compatible with the quantity needed for the analysis. This study was approved by the New York 
University Langone Medical Center Institutional Review Board. 
 
Hair analyses 
Hair samples were analyzed in their full length. The average length, calculated for the 80 
analyzed samples,  was 9.9 cm (median 9.0 cm). Assuming normal hair growth rate (25), the 
corresponding mean time frame is approximately 1 cm = 1 month. A minimum quantity of 20 mg 
was needed to perform the analysis. The collected specimens were tested using three previously 
published and validated methods using UHPLC-MS/MS. One (26) was used to screen each sample 
for 11 common drugs of abuse or metabolites: morphine, 6-acetylmorphine, codeine, amphetamine 
(AMP), methamphetamine, 3,4-methylenedioxyamphetamine (MDA), 3,4-
methylenedioxymethylamphetamine (MDMA), 3,4-methylenedioxyethylamphetamine (MDEA), 
cocaine, benzoylecgonine, and ∆9-tetrahydrocannabinol (THC). The second method (27) was 
addressed to detect the most expected and common NPS (26 substances) — namely stimulants 
(primarily synthetic cathinones) and psychedelic substituted phenethylamines: mephedrone, 3-
methylmethcathinone (3-MMC), 4-methylethcathinone (4-MEC), methylone, 4-fluoroamphetamine 
(4-FA), 3,4-methylenedioxypyrovalerone (MDPV), pentedrone, ethcathinone, alpha-
pyrrolidinovalerophenone (α-PVP; a.k.a.: “Flakka”), butylone, buphedrone, 25I-NBOMe, 25C-
NBOMe, 25H-NBOMe, 25B-NBOMe, 2C-P, 2C-B, 1-(benzofuran-5-yl)-N-methylpropan-2-amine 
(5-MAPB), 5-(2-aminopropyl)benzofuran (5-APB)/6-(2-aminopropyl)benzofuran (6-APB), para-
methoxymethamphetamine (PMMA), para-methoxyamphetamine (PMA), amfepramone, meta-
chlorophenylpiperazine (mCPP), and bupropione, plus 5 dissociative drugs, namely methoxetamine 
(MXE), phencyclidine (PCP), 4-methoxyphencyclidine (4-MeO-PCP), diphenidine, and ketamine. 
The new designer drug mCPP can be detected in biological fluids as a metabolite of trazodone 
(28,29); therefore, trazodone was also included in our method in order to discriminate between 
direct mCPP intake and biotransformation of trazodone. The limits of detection of the analytical 
methods (26,27) were set as the minimum criterion to identify the positive samples. Hair samples 
were also screened for synthetic cannabinoids. Our existing method for synthetic cannabinoids (15) 
was updated by introducing the following compounds: MAM-2201, UR-144, XLR-11, AKB-48, 
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STS-135, PB-22, AB-PINACA, 5F-AB-PINACA, ADB-PINACA, AB-FUBINACA, ADBICA, 
JWH-302, AM-2233, CB-13, JWH-016, JWH-098, JWH-147. The total number of targeted analytes 
in the latter method was 40. Altogether, each sample was screened for 82 drugs and metabolites.  
 
RESULTS  
Eighty samples collected from different parts of the body were analyzed, 57 of which detected 
positive for at least one substance—either a traditional or new drug. Among these, 36 samples were 
head hair, 3 were leg hair, and in 18 cases the sampling site was not recorded. Among positive 
specimens, 40.4% (n=23) were provided by female participants. Donors mainly identified as White 
(n=35, 61.4%), while other ethnic groups included Hispanic (n=12, 21.0%), Asian (n=4, 7.0%) or 
other/mixed (n=6, 10.6%). Among positive samples (n=57), 31 tested positive for the exclusive 
presence of traditional drugs, 2 were positive for NPS only, while in the remaining 24 cases of 
traditional drugs were als  positive for at least one NPS. No sample tested positive for synthetic 
cannabinoids. Among traditional drugs, THC was detected in 35 samples (range 0.02−1.92 ng/mg, 
mean=0.34 ng/mg, median=0.11 ng/mg), MDMA in 26 samples (range 0.08−7.17 ng/mg, 
mean=1.43 ng/mg, median= 0.68 ng/mg), amphetamine in 15 samples (range 0.04−1.68 ng/mg, 
mean=0.52 ng/mg, median= 0.33 ng/mg), ketamine in 11 samples (range 0.21−11.1 ng/mg, 
mean=1.90 ng/mg, median= 0.68 ng/mg), and cocaine in 25 samples (range 0.10−33.5 ng/mg, 
mean=4.13 ng/mg, median= 1.83 ng/mg). MDA, possibly arising from the metabolism of MDMA, 
was measurable in 18 samples (range 0.01−0.70 ng/mg, mean=0.19 ng/mg, median= 0.14 ng/mg). 
In all 25 samples that tested positive for cocaine, the benzoylecgonine metabolite was also detected 
(range 0.01−4.34 ng/mg, mean=0.74 ng/mg, median= 0.38 ng/mg). Two samples positive to 
amphetamine (0.04 ng/mg and 0.52 ng/mg) were also positive for methamphetamine at similar 
levels (0.01 ng/mg and 0.34 ng/mg, respectively), suggesting that the former drug was likely present 
as metabolite of the latter. One sporadic finding of MDEA at the concentration of 0.34 ng/mg was 
recorded. The remaining analytes considered in the analytical method have never been identified in 
any of the analyzed samples.  
Multiple positivity related to sole use of multiple traditional drugs was detected in 31 cases.  
Figure 1 presents the percentage of the sample positive for one drug, two, three, and four drugs, 
respectively, for each class of traditional compounds. More than 30% of participants who tested 
positive for MDMA or THC appear to have been inclined to use only that single substance. On the 
other hand, the large majority of participants who used cocaine and ketamine also tested positive for 
other substances. However, it is unknown whether multiple drugs were used concomitantly or at 
different points in time.  
As shown in Table 1, 26 samples tested positive for at least one NPS. Among these, 9 
samples were positive for two or more NPS. Positive specimens were almost equally distributed 
between males (n=14; 53.8%) and females (n=12; 46.2%). The most common NPS detected was 
butylone, which was found in 25 samples, often at high concentrations (range < 7−4900 pg/mg, 
mean=440 pg/mg, median= 21 pg/mg). Other multiple detection included methylone (5 cases; range 
<6−98 pg/mg), methoxetamine (4 cases; range 3−19 pg/mg), 5/6-APB (1 case; 82 pg/mg), α-PVP (1 
case; 6 pg/mg), and 4-FA (1 case; 29 pg/mg). Multiple positive findings that include at least one 
traditional drug of abuse and one NPS were detected in 24 cases. Eight samples tested positive for 
five or more drugs. Traditional drugs detected in association with NPS were MDMA (17 cases), 
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THC (15 cases), cocaine (15 cases), amphetamine (8 cases), ketamine (6 cases), and 
methamphetamine (1 case). While butylone was detected in a wide range of concentrations, with 9 
samples above 100 pg/mg, the measured levels for the remaining NPS was interestingly below 100 
picograms of drug per milligrams of hair, either suggesting sporadic exposure to these substances or 
low rate of incorporation into the keratin matrix.  
 
DISCUSSION  
Our study shows that NPS were detected in a large number of NYC nightclub and dance 
festival attendees—a high risk population. Methylone, butylone, and methoxetamine were detected 
exclusively or more often concurrently in 25 out of 26 cases which tested positive for at least one 
NPS. Our previous work has already shown that many nightclub and dance festival attendees 
reporting MDMA use tested positive for methylone and/or butylone, with four out of ten self-
reported MDMA/ecstasy/Molly users testing positive for these drugs after reporting no use of 
synthetic cathinones or unknown pills or powders (13). NPS are often identified at festivals as being 
sold in place of traditional drugs—primarily ecstasy/Molly. The fact that synthetic cathinones are 
often falsely represented as a pure form of ecstasy to MDMA users has been verified in the past 
(30). Likewise, ketamine is often replaced or adulterated with methoxetamine. Therefore, it is not 
unlikely that most of our positive findings would be unexpected by the users and can be attributed 
to unaware intake of NPS. 
Synthetic cannabinoids were not detected in any of the tested hair samples. In the present 
study, it is possible that the panel of target analytes covered by our method did not fully reproduce 
the NYC scenario at the time of sample collection. While it is possible that some newly-introduced 
synthetic cannabinoids were out of the range of the targeted substances, it should also be noted that 
different groups of synthetic drugs are expected to be used by different social groups. Nightclub 
attendees and partygoers are likely to use synthetic cathinones, not synthetic cannabinoids, whereas 
other social groups (31) might resort to synthetic cannabinoids as cheap but more potent substitute 
of THC to temporarily escape from personal or social problems, such as unemployment, 
homelessness, and/or incarceration (32).  
It should be noted that prevalence of use of specific NPS—particularly synthetic 
cathinones—is constantly shifting. According to national seizure data, for example, prevalence of 
confiscations of synthetic cathinones fluctuated greatly between 2013 and 2015 (33). For example, 
methylone was the most confiscated compound in 2013 (71.8%) and this decreased to 30.7% and 
2.3% in 2014 and 2015, respectively. Various other synthetic cathinones (e.g., MDPV) rapidly 
decreased in prevalence (or virtually disappeared) over the three year period. Therefore, it is 
possible that other/newer compounds were used and not detected.  
 
 
CONCLUSIONS  
The present study demonstrates that hair testing offers a unique perspective in the 
investigation of drug consumption, provided that a large panel of target analytes is considered. The 
extended diagnostic time-window covered by the keratin matrix (unlike urine, blood, and oral fluid) 
allows retrospective investigation of drug prevalence and diffusion of any targeted psychoactive 
substance among selected populations. Furthermore, clues about occasional (even sporadic intake) 
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vs. heavy NPS use are made possible by quantitative results of hair testing. In particular, the present 
study highlighted the wide occurrence of poly-use and likely unintentional intake of unknown NPS 
in the NYC area. The prevalent diffusion of synthetic cathinones as recreational drugs, often used in 
combination with other more traditional drugs, was clearly evident in the data, relative to young 
consumers attending EDM parties at nightclubs and dance festivals. Butylone was the most 
frequently detected NPS, followed by methylone and methoxetamine. 
In prospect, the limitations concerning the specific population under study will be 
surmounted by investigating broader groups of young people. Similar occurrences are expected for 
social groups more inclined to use synthetic cannabinoids, since the composition of “legal highs” 
sold in the black market is typically variable, implicating that consumers do not have control over 
the quality of the product they are using, potentially increasing risk of serious health threat. Large 
NPS screening panels using hair testing and taking into account the timely fluctuation of the market 
situation can also be applied to other individuals under periodic control (e.g., in workplace control 
or driving re-licensing) to check how frequently NPS are used in substitution of traditional drugs to 
escape a positive outcome.  
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  Table 1. Results from samples which tested positive for at least one NPS (concentrations are given in pg/mg) 
Subject New Psychoactive Substances Traditional drugs of abuse 
Case Sex 
Ethnic 
group 
Hair 
type 
Length 
(cm) 
Butylone Methylone MXE 5/6-APB α-PVP 4-FA AMP mAMP MDMA COC KET THC 
1 F White head 25    82 
  
  1600    
2 M White leg 2.5 600 98  
 
6 
 
  6300 1200  150 
3 M White leg 2 100   
   
      
4 F Hispanic head 12 290   
   
  630 5600 680  
5 F White head 12 < 7   
   
280   13000   
6 F Hispanic head 25 17 8  
   
  1040 1800 2050 240 
7 F White head 12 17  13 
   
  160 5200 1400 60 
8 M White head 12 < 7  19 
   
220  710 9400 1600 80 
9 F Other/mixed head 7 < 7   
   
      
10 M Hispanic head 12 4900 10  
   
  350   1200 
11 M White head 8 < 7  3 
   
120  130 1600 310  
12 M White head 4.5 < 7   
   
  320    
13 M Other/mixed head 23 < 7   
   
40 10 1500 5800 420 20 
14 F Hispanic head 23 < 7   
   
     30 
15 M Hispanic head 8 25   
   
   150  40 
16 F Asian n/a 12 23   
   
     850 
17 M Other/mixed n/a 7 110   
   
950  3100 6200  190 
18 F Asian head 23 < 7   
   
1700  1900    
19 M Hispanic head 12 120   
   
540  540 2600  90 
20 F Hispanic head 7 200   
   
     120 
21 M Hispanic head 11 < 7   
   
  80    
22 M White head 4.5 21   
  
29   710 1100   
23 F Hispanic head 12 < 7 < 6 5 
   
110  1200 3400  290 
24 M White head 6 300 < 6  
   
  120 1400   
25 F Hispanic head 10 190   
   
     940 
26 M White head 4 38   
   
   34000  380 
 Positive samples  25 5 4 1 1 1 8 1 17 15 6 15 
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Figure 1. Percentage of the sample positive for one drug, two, three, and four drugs, respectively, 
for each class of traditional compounds. Positivity related to sole use of multiple traditional drugs 
was detected in 31 cases.   
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